Rivian vs Sanofi

Lawmakers Approve AM Radio Mandate for US Automakers

The US House of Representatives has overwhelmingly passed the AM Radio for Every Vehicle Act, which would require automakers to include AM radio in new vehicles at no extra cost. The bill now heads to the Senate, where it has bipartisan support with key sponsors including Senators Ed Markey and Ted Cruz. Proponents argue AM radio is crucial for emergency alerts, while automakers like Tesla, Rivian, and BMW have been dropping the feature, often citing electromagnetic interference from electric motors. This legislation could impact the automotive and broadcast industries by preserving AM radio's reach. The bill's future hinges on the Senate vote.

• House passed AM Radio for Every Vehicle Act with bipartisan support.
• Bill directs NHTSA to require AM radio in new vehicles as standard equipment.
• Senators Markey and Cruz co-sponsor Senate version with 60 co-sponsors.

8-K Financial Filing Analysis for Rivian (2026-08-27)

Rivian Automotive, Inc. hat bekannt gegeben, dass Chief Financial Officer Claire McDonough ihr Amt mit Wirkung zum 30. Oktober 2026 niederlegt, um eine neue berufliche Chance wahrzunehmen und an die Ostküste umzuziehen. Das Unternehmen betonte, dass der Rücktritt einvernehmlich erfolgt und keine Differenzen bezüglich Finanzberichterstattung, internen Kontrollen oder operativen Abläufen vorliegen. McDonough verbleibt bis Ende Oktober im Amt, um einen geordneten Übergang zu gewährleisten. Derek Mulvey, seit 2021 Vice President of Finance, soll interimistisch die CFO-Rolle übernehmen, während ein strukturierter Suchprozess für die dauerhafte Nachfolge läuft.

• CFO Claire McDonough reichte am 24. August 2026 ihren Rücktritt mit Wirkung zum 30. Oktober 2026 ein; es bestehen keine bilanziellen oder operativen Differenzen.
• Derek Mulvey, seit 2021 Vice President of Finance, soll nach McDonoughs Ausscheiden als Interim-CFO fungieren.
• Rivian hat einen formellen internen und externen Suchprozess zur Bestimmung eines dauerhaften Chief Financial Officer eingeleitet.

Investor Guide: TechCrunch Disrupt 2026

TechCrunch’s investor guide to Disrupt 2026 outlines how investors can use the October 13–15 conference at Moscone West to source startups, network, and gather market intelligence. Highlights include access to 200 vetted, pre-Series A startups in the Startup Battlefield 200 (competing for $100,000 in equity-free funding), curated investor programming across multiple stages (Smart Money, Smart Systems, AI), and Investor Pass perks such as the Deal Flow Café, an early founder list, and AI-assisted curated 1:1 meetings. The article notes past speakers and this year’s speaker lineup, the volume of curated meetings, and time-limited ticket discounts of up to $300 (discount period referenced in the article).

• TechCrunch Disrupt 2026 is scheduled for October 13–15, 2026 at Moscone West in San Francisco.
• Startup Battlefield 200 features 200 pre-Series A startups competing for $100,000 in equity-free funding.
• Startup Battlefield alumni have collectively raised over $32 billion and produced more than 250 exits.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

Am 17. September 2026 reichte Sanofi ein Form 6-K bei der U.S. Securities and Exchange Commission ein, das eine Pressemitteilung vom 14. September 2026 beinhaltet. Die Einreichung kündigt eine neue strategische Partnerschaft zwischen Sanofi und Cheplapharm im Bereich etablierter Medikamente (Mature Medicines) an. Diese Partnerschaft unterstreicht Sanofis kontinuierliche Strategie zur Portfolio-Optimierung, um etablierte pharmazeutische Produkte effizienter zu verwalten oder zu monetarisieren und Ressourcen auf innovative Pipeline-Therapien und Kernwachstumstreiber zu fokussieren.

• Sanofi hat eine strategische Partnerschaft mit Cheplapharm für sein Portfolio an etablierten Medikamenten (Mature Medicines) geschlossen, die am 14. September 2026 per Pressemitteilung bekannt gegeben wurde.
• Die Form 6-K-Meldung wurde am 17. September 2026 offiziell von Alexandra Roger, Head of Legal Corporate & Finance, unterzeichnet und eingereicht.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.